[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569334":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":28,"responsibleParty":47,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of Vermont","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adults with Myelodysplastic syndromes",null,"All participants will be in one group. Participants will by adults with Myelodysplastic syndromes. Blood will be taken at regular appointments that are part of standard care.",[13],"Other: Observational",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observational","Blood will be collected from one cohort to identify potential blood biomarkers.",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Diego Adrianzen Herrera, MD","CONTACT","(802) 656-2021","dadrianz@med.uvm.edu",{"name":26,"role":22,"phone":23,"phoneExt":10,"email":27},"Neil A Zakai, MD","neil.zakai@med.uvm.edu",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Burlington","Vermont","05495-2038","United States",{"type":36,"coordinates":37},"Point",[38,39],-73.21207,44.47588,{"lat":39,"lon":38},[42,45],{"name":21,"role":22,"phone":43,"phoneExt":10,"email":44},"(802) 656-4414","dadrianz@uvm.edu",{"name":21,"role":46,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Diego Adrianzen Herrera","Medical Oncologist, Assistant Professor","100569334",false,"NCT06692894","Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes","Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤3\n* Expected survival of at least 6 months\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis\n* Hematopoietic stem cell transplantation expected within 6 months","ALL","18 Years",{"count":59,"type":60},30,"ESTIMATED","OBSERVATIONAL","Why Is This Research Study Being Conducted?\n\n* The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke.\n* Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients.\n* By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS",[64],"Myelodysplastic Syndromes, Adult",[66,67],"Myelodysplastic Syndromes","Hematology","2026-02-02",{"date":70,"type":71},"2026-02-03","ACTUAL",{"date":73,"type":71},"2024-11-05",{"date":75,"type":60},"2027-11",{"name":5,"class":6},1]